本頁面由Tiger Trade Technology Pte. Ltd.提供服務

諾瓦瓦克斯醫藥

9.42
+0.12001.29%
盤後9.500.0799+0.85%19:59 EDT
成交量:612.15萬
成交額:5,893.32萬
市值:15.49億
市盈率:-6.21
高:9.87
開:9.29
低:9.23
收:9.30
52周最高:11.97
52周最低:6.20
股本:1.64億
流通股本:1.43億
量比:1.18
換手率:4.28%
股息:- -
股息率:- -
每股收益(TTM):-1.5181
每股收益(LYR):2.58
淨資產收益率:-898.20%
總資產收益率:-6.51%
市淨率:-8.12
市盈率(LYR):3.65

資料載入中...

2024/06/18

關聯方擬減持公告

Form144|諾瓦瓦克斯公司董事James F.Young擬減持15000股,總價約20.57萬美元
2024/06/17

關聯方擬減持公告

Form144|諾瓦瓦克斯高管Filip Dubovsky擬減持13904股,總價約20萬美元
2024/06/14

重要事件披露

Form 8-K - Current report
2024/06/06

重要事件披露

Form 8-K - Current report
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/05/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/05/13

重要事件披露

Form 8-K - Current report
2024/05/10

重要事件披露

Form 8-K - Current report
2024/05/10

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/07

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/26

重要事件披露

Form 8-K - Current report
2024/04/15

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/15

超過5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/03/26

重要事件披露

Form 8-K - Current report
2024/02/28

重要事件披露

Form 8-K - Current report
2024/02/28

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/22

重要事件披露

Form 8-K - Current report
2024/02/14

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/31

重要事件披露

Form 8-K - Current report